Dabomb Protein Biotech (ROCO:6578) EBIT: NT$-63.3 Mil (TTM As of Dec. 2025)


ROCO:6578 Dabomb Protein Biotech Corp ROCO:6578
61 GF Score
Price NT$16.10
GF Value NT$14.62
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Dabomb Protein Biotech EBIT?

Dabomb Protein Biotech ROCO:6578 61 EBIT is NT$-63.3 Mil as of Dec. 2025. GuruFocus rates ROCO:6578 with a GF Score™ of 61/100 and a GF Value™ of NT$14.62 (Fairly Valued). The stock has 1 warning sign investors should review.

Dabomb Protein Biotech's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-41.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-63.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dabomb Protein Biotech's annualized ROC % for the quarter that ended in Dec. 2025 was -4.66%. Dabomb Protein Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -19.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dabomb Protein Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -5.90%.


Dabomb Protein Biotech  (ROCO:6578) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dabomb Protein Biotech's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-44.98 * ( 1 - 0% )/( (1004.153 + 924.81)/ 2 )
=-44.98/964.4815
=-4.66 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1190.637 - 42.082 - ( 219.954 - max(0, 138.653 - 283.055+219.954))
=1004.153

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1095.76 - 29.762 - ( 160.635 - max(0, 84.488 - 225.676+160.635))
=924.81

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Dabomb Protein Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-167.716/( ( (869.892 + max(19.547, 0)) + (832.986 + max(34.289, 0)) )/ 2 )
=-167.716/( ( 889.439 + 867.275 )/ 2 )
=-167.716/878.357
=-19.09 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(30.518 + 25.066 + 6.045) - (42.082 + 0 + 0)
=19.547

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.971 + 19.048 + 5.064) - (29.762 + 0 + 0.031999999999996)
=34.289

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dabomb Protein Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-63.27/1071.838
=-5.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dabomb Protein Biotech EBIT Related Terms


Dabomb Protein Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Dabomb Protein Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dabomb Protein Biotech EBIT Chart

Dabomb Protein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.04 -42.48 -47.72 21.27 -63.27

Dabomb Protein Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 4.30 -17.07 -8.57 -41.93

ROCO:6578 vs KHC, GIS: EBIT Comparison

For the Packaged Foods subindustry, Dabomb Protein Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dabomb Protein Biotech EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dabomb Protein Biotech's EV-to-EBIT falls into.


ROCO:6578
61GF Score
Dabomb Protein Biotech Corp ROCO:6578
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dabomb Protein Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-63.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-63.3 Mil mean?
Dabomb Protein Biotech (ROCO:6578) has a EBIT of NT$-63.3 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dabomb Protein Biotech.
Is Dabomb Protein Biotech's EBIT too high?
Dabomb Protein Biotech's current EBIT is NT$-63.3 Mil. Overall, Dabomb Protein Biotech has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's EBIT compare to KHC and GIS?
Dabomb Protein Biotech's EBIT of NT$-63.3 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dabomb Protein Biotech. Dabomb Protein Biotech's current EBIT is NT$-63.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$14.62, compared to a current price of NT$16.10 — trading 10.1% above its estimated fair value. The current EBIT is NT$-63.3 Mil. Dabomb Protein Biotech's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current EBIT is NT$-63.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?

Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued. The current stock price of NT$16.10 is trading 10.1% above its estimated GF Value™ of NT$14.62. GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.

Key valuation signals for ROCO:6578:

  • EBIT: NT$-63.3 Mil
  • GF Value™: NT$14.62 vs. price of NT$16.10 (10.1% above fair value)
  • GF Score™: 61/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dabomb Protein Biotech Business Description

Address No. 52, Industrial 3rd Road, Annan District, Tainan, TWN, 709
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
61GF Score

Get the complete analysis for ROCO:6578

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.10
Price
NT$14.62
GF Value